Wrist Actigraphy Algorithm Quantifies Narcolepsy Burden in Nap-Free Days

A wrist-worn actigraphy algorithm distinguished people with narcolepsy type 1 from healthy controls by a wide margin: patients averaged about four nap-free days per month, compared with 17 for age- and sex-matched controls, and slept about 34 more minutes during the day. The study, published in SLEEP and sponsored by Takeda Development Center Americas Inc., positions nap-free days as an objective, at-home measure of symptom burden and treatment response in a disorder where clinicians have long relied on tools that capture neither real life nor reliable recall.

Why existing measures fall short

Excessive daytime sleepiness (EDS) is the hallmark symptom of narcolepsy type 1 (NT1), a condition marked by the loss of orexin-producing neurons and, for roughly 90% of patients, daytime napping as a critical coping mechanism. Clinicians typically assess sleepiness in two ways. The subjective route is the Epworth Sleepiness Scale (ESS), a questionnaire that depends on patient memory and can skew results. The objective route is the in-lab Maintenance of Wakefulness Test (MWT), in which patients attempt to stay awake in a dimly lit room. The MWT is time-consuming, and a single lab session does not always reflect daily life. ESS scores, notably, may not track MWT results at all.

Standard wrist-worn actigraphy was built for nighttime sleep and fails at detecting daytime naps for a simple mechanical reason: it mistakes any period of non-movement for sleep.

How the algorithm works

The researchers trained the algorithm on data from 2,151 participants without narcolepsy in the Multi-Ethnic Study of Atherosclerosis (MESA), using manually annotated naps from seven days of actigraphy. The discrimination logic is straightforward. Study co-author Dmitri Volfson, PhD, vice president and head of quantitative sciences at Takeda, said: "We found that falsely detected naps tended to be short and include small, occasional movements, whereas real naps were longer and almost completely still. Removing those short or restless periods made a big difference."

The team then evaluated and refined the algorithm in clinical trials of people with NT1.

What the trials measured

Two datasets anchor the clinical claims:

• In an observational study, people with NT1 logged about four nap-free days per month versus 17 for matched controls, and slept roughly 34 additional minutes during the day.
• In a phase 2 trial of Takeda's orexin receptor 2–selective agonist, participants gained about six to 12 nap-free days and napped 12 to 33 fewer minutes than at baseline.

The phase 2 figures are measured trial results; the broader claim that the algorithm will prove useful in routine care remains a projection the authors themselves frame as work in progress.

Do diaries still matter?

The study also interrogated sleep diaries, a low-cost staple of sleep medicine. Self-reported naps showed poor overlap with device-detected naps, and some participants even logged their in-clinic MWT sessions as naps. Yet co-first author Raúl Torres, MS, associate director of statistics at Takeda, argues the diaries retain value: "They tell you things a wrist device can't, such as why someone napped, how they felt afterward, and whether a nap was planned."

Torres frames the device as additive rather than disruptive: "passive, objective measurement of what actually happens over weeks at home. I see it as a complement to these tools rather than a replacement." He adds that a metric like nap-free days may give clinicians and patients a shared, concrete language for discussing how treatment is going.

One caveat the authors themselves flag: the decision to nap depends not only on sleepiness but on opportunity. Access to a quiet space and work schedules both constrain whether a sleepy patient can nap at all, which means nap counts partially reflect circumstances rather than pure symptom severity.

What comes next

Torres says the team is "working to make these measures useful outside of clinical trials," including an app that would let people starting new treatments "follow their own progress and share objective measures with their clinicians in the real world." On the technical roadmap are a flexible time window that tracks when each individual actually sleeps rather than a fixed daytime period, plus the addition of heart rate or more detailed accelerometry (motion sensing) to improve accuracy.

For sleep clinics and trial sponsors, the near-term takeaway is a validated endpoint candidate; the wider deployment depends on the planned refinements clearing real-world use.